Chinese authorities granted Zhejiang Hisun Pharmaceutical (SHA:600267) a clinical trial approval for the HS387 tablets for ovarian and non-small cell lung cancer, according to a Wednesday filing with the Shanghai bourse.
The drug will be tested in patients with advanced solid tumors, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments